In stark contrast to a few decades ago when lung cancer was predominantly a disease of
men who smoke, incidence rates of lung cancer in women are now comparable to or higher …

Lung cancer remains the leading cause of cancer-related deaths worldwide in women and
men. In incidence, lung cancer ranks second, surpassed by breast cancer in women and …

Background Limited evidence exists to show that adding a third agent to platinum-doublet
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …

Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the
Era of Precision Oncology. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …

Introduction Women tend to survive a lung cancer diagnosis longer than men; however
potential drivers of this sex-related disparity remain largely elusive. We quantified factors …

Effective administration of traditional cytotoxic chemotherapy is often limited by off-target
toxicities. This clinical dilemma is epitomized by cisplatin, a platinating agent, which has …

Lung cancer remains a significant health problem worldwide for both men and women and
is the leading cause of cancer death in many countries. Age-adjusted lung cancer incidence …

Splicing abnormalities frequently occur in cancer. A key role as splice site choice regulator is
played by the members of the SR (Ser/Arg-rich) family of proteins. We recently demonstrated …

Simple Summary Immune checkpoint inhibitors (ICIs) have transformed the treatment
paradigm for metastatic non-small cell lung cancer (NSCLC) patients (IB-IIIA) with no …